Efficacy of Acetaminophen-ibuprofen Combination on the Postoperative Pain After Thyroidectomy
Overview
Acetaminophen and ibuprofen has been safely used for a long time and reduces postoperative pain and opioid dosages. Investigators are planning to compare the efficacy of 1) acetaminophen only and 2) acetaminophen and ibuprofen combination at postoperative pain after thyroidectomy.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Study Primary Completion Date: October 2023
Detailed Description
Acetaminophen and ibuprofen has been safely used for a long time and reduces postoperative pain and opioid dosages. Investigators are planning to compare the efficacy of 1) acetaminophen 1g only and 2) the combination of acetaminophen 1g and ibuprofen 300mg at postoperative pain after thyroidectomy. Some recovery valuables such as the postoperative pain and opioid requirements will be assessed
Interventions
- Drug: Acetaminophen
- acetaminophen 1g iv dripping at end of surgery
- Drug: Ibuprofen
- ibuprofen 300mg iv dripping at end of surgery
Arms, Groups and Cohorts
- Active Comparator: control group
- acetaminophen 1g iv dripping
- Experimental: experimental group
- the combination of acetaminophen 1g and ibuprofen 300mg iv dripping
Clinical Trial Outcome Measures
Primary Measures
- postoperative pain
- Time Frame: during 30 minutes after surgery
- the maximal postoperative pain severity using pain scale(visual analogue scale; 0 cm=no pain; 10 cm=the worst pain)
Secondary Measures
- pain killer requirement
- Time Frame: during 30 minutes after surgery
- the incidence of the patients who require pain killer
Participating in This Clinical Trial
Inclusion Criteria
- the patients undergoing scheduled thyroidectomy – American Society of Anesthesiologists status 1 or 2 Exclusion Criteria:
- refusal to be enrolled in the study – emergency surgery – hepatic or renal disease – on chronic pain medications – psychiatric disorders – pregnancy, lactation – allergy or contraindication to the study drug
Gender Eligibility: All
Minimum Age: 20 Years
Maximum Age: 65 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- The Catholic University of Korea
- Provider of Information About this Clinical Study
- Principal Investigator: Young Eun Moon, professor – The Catholic University of Korea
- Overall Official(s)
- youngeun moon, MD, PhD, Principal Investigator, Seoul St. Mary’s Hospital
- Overall Contact(s)
- youngeun moon, MD, PhD, 822-2258-6163, 0910momo@naver.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.